Vectra AI Platform Now Available for Purchase on the CrowdStrike Marketplace
New CrowdStrike Marketplace delivers one-stop shop to reduce risk and cybersecurity stack complexity on the…
Month: September 2023
NordPass introduced passkey support for iPhone users
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) — With Apple rolling out its latest operating system,…
Motorq Joins Forces with Leading OEM to Revolutionize Fleet Analytics and Connected Vehicle Insights
SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) — Motorq, the leading connected vehicle analytics and…
The Technical Traders Ltd. Unveils Asset Revesting Signals: A Game-Changer in Investment and Capital Protection
Toronto, Ontario–(Newsfile Corp. – September 18, 2023) – Amidst the ever-evolving financial landscape, The Technical…
Ennova Holdings Launches Upgrade ‘TIER’ to Empower Africa’s Financial Future Through Blockchain Innovation
Cape Town, South Africa, Sept 18, 2023 – (ACN Newswire) – Ennova Holdings, a forward-thinking…
United Arab Emirates Becomes First Country to Hold Fully Digital Elections with Scytl
BARCELONA, SPAIN, Sept 18, 2023 – (ACN Newswire) – Scytl, leader in online voting and…
Doubleview Reports the Exploration Model and 2023 Diamond Drilling Targets at the Hat Polymetallic Deposit
Vancouver, British Columbia–(ACN Newswire – September 18, 2023) – Doubleview Gold Corp. (TSXV: DBG) (OTCQB:…
Pantaleon and C3 AI Partner to Modernize Sugar Industry, Transforming Harvesting Operations
Top global sugar producer projects up to $5 million benefit using C3 Generative AI REDWOOD…
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused…
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused…
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)…
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)…
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
– Topline results from this study are expected in early Q1 2024 – Celltrion has…